Samuel Waxman Cancer Research Foundation Appoints Alan Rosmarin, M.D., Chief Mission Officer


The Samuel Waxman Cancer Research Foundation (SWCRF) today announced its appointment of Alan G. Rosmarin, M.D., to the position of Chief Mission Officer. Dr. Rosmarin assumes the responsibilities of SWCRF Chief Mission Officer while continuing as Chief of the Division of Hematology/Oncology and Co-Director of the UMass Memorial Cancer Center of Excellence in Worcester, MA.

“We are delighted to recognize Alan Rosmarin’s countless contributions to our mission over the years with this important new role within our organization,” said Samuel Waxman Cancer Research Foundation founder and CEO Samuel Waxman, M.D. “Alan has been instrumental in shaping the vision of our scientific leadership with his expertise and passion for fostering innovative cancer research, which makes him uniquely qualified to serve as our Chief Mission Officer.”

Dr. Rosmarin takes on his expanded role within SWCRF’s scientific leadership team after serving for two years as co-chair of the foundation’s Scientific Advisory Board, a body of leading cancer scientists who review the quality and impact of the SWCRF’s research programs. As Chief Mission Officer, Dr. Rosmarin, collaborating closely with SWCRF Chief Scientific Officer Jonathan D. Licht, M.D., will lead an effort to strategically build the scientific mission of SWCRF and assure its implementation while facilitating the activities of the collaborating cancer investigators who make up SWCRF’s Institute Without Walls. 

About Alan G. Rosmarin, MD

Alan G. Rosmarin, MD is the Gladys Smith Martin Professor of Oncology at the University of Massachusetts Medical School. He serves as Chief of the Division of Hematology/Oncology and Co-Director of the UMass Memorial Cancer Center of Excellence, which provides expert diagnosis, treatment, and support of cancer patients, as well as extensive laboratory-based and clinical/translational research. Dr. Rosmarin is expert in the clinical management of hematologic malignancies, including leukemia, lymphoma, myeloma, and other blood disorders. His laboratory-based research is focused on the control of gene expression and growth properties of blood stem cells and leukemia. He serves as a reviewer of manuscripts and grant applications, and he is a member of the editorial boards of Stem Cells, Experimental Hematology, and the American Cancer Society Cancer Information Database. Dr. Rosmarin has served significant national roles in the American Cancer Society, the National Cancer Institute, and the American Society of Hematology.

About Samuel Waxman Cancer Research Foundation

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients. Through the Foundation’s collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded more than $85 million to support the work of more than 200 researchers across the globe.